Status:
COMPLETED
Chemotherapy Induced Peripheral Neuropathy (CIPN) and Lymphoma Longitudinal Follow-up and Prognostic Factors
Lead Sponsor:
Centre Hospitalier Régional d'Orléans
Conditions:
Lymphoma
Peripheral Neuropathy
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Vincristine-induced peripheral neuropathy, which is commonly a sensorimotor neuropathy, remains a major complication of lymphoma patients treated with R-CHOP. The investigators propose a clinical, ele...
Detailed Description
Patients with lymphoma will be evaluated before chemotherapy (T1), after 4 cycles (T2), at the end of the chemotherapy treatment (If more than 4 cycles) (T3) and 6 month after the end of chemotherapy ...
Eligibility Criteria
Inclusion
- Diagnosis of indolent or aggressive B/T NHL confirmed by biopsy and requiring chemotherapy after PCR decision including vincristine, RCHOP/CHOP protocol or CHOEP
- Accept to participate in the study
- Age \> 18 year
- Able and willing to provide informed consent
- Affiliated to a social security system
Exclusion
- Life-threatening emergency requiring chemotherapy in extreme urgency
- Neuro-meningeal damage at diagnosis
- Protected person (under guardianship or curators)
- Person under court protection
- Pregnant or breastfeeding woman
- Persons deprived of liberty by judicial or administrative decision
- Persons under forced psychiatric care
- Persons admitted to a health or social institution for purposes other than research
- Persons unable to express their consent
Key Trial Info
Start Date :
January 10 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 11 2025
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT05378256
Start Date
January 10 2022
End Date
March 11 2025
Last Update
April 17 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHR Orléans
Orléans, France, 45067